Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:rilpivirine
gptkb:Rilpivirine |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
hypersensitivity to rilpivirine
|
| gptkbp:dosage_form |
25 mg once daily
|
| gptkbp:effective_date |
2011-08-10
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Edurant
|
| gptkbp:ingredients |
gptkb:rilpivirine
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
J05 A E04
|
| gptkbp:is_used_for |
treatment of HIV
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:packaging |
blister pack
|
| gptkbp:side_effect |
gptkb:historical_event
rash insomnia |
| gptkbp:social_structure |
C22 H21 N3 O2 S
|
| gptkbp:storage |
room temperature
|
| gptkbp:supports |
granted
|
| gptkbp:traded_on |
gptkb:Edurant
|